Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
17.83
+0.41 (2.35%)
At close: Sep 25, 2026, 4:00 PM EDT
17.79
-0.04 (-0.22%)
After-hours: Sep 25, 2026, 4:35 PM EDT
Viatris Employees
Viatris had 30,000 employees as of December 31, 2025. The number of employees decreased by 2,000 or -6.25% compared to the previous year.
Employees
30,000
Change (1Y)
-2,000
Growth (1Y)
-6.25%
Revenue / Employee
$491,243
Profits / Employee
-$13,690
Market Cap
20.48B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 30,000 | -2,000 | -6.25% |
| Dec 31, 2024 | 32,000 | -6,000 | -15.79% |
| Dec 31, 2023 | 38,000 | 1,000 | 2.70% |
| Dec 31, 2022 | 37,000 | 0 | - |
| Dec 31, 2021 | 37,000 | -8,000 | -17.78% |
| Dec 31, 2020 | 45,000 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,029 |
| Teva Pharmaceutical Industries | 33,950 |
| Dr. Reddy's Laboratories | 27,527 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
VTRS News
- 2 days ago - Viatris initiated with an Outperform at Oppenheimer - TheFly
- 9 days ago - Viatris announces approval for Wakix in Japan - TheFly
- 9 days ago - Viatris price target raised to $13 from $12 at Piper Sandler - TheFly
- 9 days ago - Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome - PRNewsWire
- 16 days ago - Leerink sees growth for Viatris, starts at Outperform - TheFly
- 16 days ago - Viatris initiated with an Outperform at Leerink - TheFly
- 17 days ago - Viatris price target raised to $20 from $15 at Argus - TheFly
- 7 weeks ago - Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M - TheFly